CALL - SPRINTER OPEN END - VERTEX PHARMACEUTICALS | Delayed Deutsche Boerse AG 04:35:09 2024-07-16 am EDT | ||
| 17.35 EUR | +1.23% |
|
| Current month | +7.39% | ||
| 1 month | +3.13% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 17.35 | +1.23% |
| 24-07-15 | 17.14 | +0.71% |
| 24-07-12 | 17.02 | -1.33% |
| 24-07-11 | 17.25 | +0.70% |
| 24-07-10 | 17.13 | +2.15% |
Delayed Quote Deutsche Boerse AG
Last update July 16, 2024 at 04:35 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VU8GET |
| ISIN | DE000VU8GET0 |
| Date issued | 2023-06-13 |
| Strike | 308.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.84 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 17.35 € |
|---|---|
| Lowest since issue | 4.96 € |
| Spread | 0.19 € |
| Spread % | 1.08% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
490.8
USD
Average target price
473.1
USD
Spread / Average Target
-3.62%
- Stock Market
- Certificates
- Certificat
